search
Back to results

Suprazygomatic Block in Cleft Palate Surgery in Children

Primary Purpose

Cleft Palate

Status
Completed
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
Bupivacaine
Dexmedetomidine
paracetamol
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cleft Palate focused on measuring suprazygomatic block, dexmedetomidine

Eligibility Criteria

1 Year - 5 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age between 1 and 5 years
  • Children scheduled for primary surgery for soft palate cleft or soft and hard palate clefts
  • Gender: both

Exclusion Criteria:

  • Parent refusal
  • History of developmental delay or mental retardation, which will make observational pain intensity assessment difficult
  • Hypersensitivity to any local anesthetics
  • Bleeding diathesis
  • Children with co-morbid conditions like congenital heart disease, respiratory pathology and central nervous system disorders
  • Skin lesions or wounds at the puncture site of the proposed block

Sites / Locations

  • Assiut University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Bupivacaine

Dexmedetomidine

Arm Description

Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%).

Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.

Outcomes

Primary Outcome Measures

modified Children's Hospital of Eastern Ontario Pain Scale (CHEOPS)
postoperative pain assessment in children minimum score: 4, maximum score: 13 Patients with modified CHEOPS > 6 will be given rescue analgesia

Secondary Outcome Measures

time to first analgesia
time of intravenous paracetamol requirment postoperatively
5-point Likert scale
parent satisfaction score (1 = very satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied, 5 = very dissatisfied)

Full Information

First Posted
January 21, 2018
Last Updated
September 21, 2018
Sponsor
Assiut University
search

1. Study Identification

Unique Protocol Identification Number
NCT03412474
Brief Title
Suprazygomatic Block in Cleft Palate Surgery in Children
Official Title
Evaluation of Postoperative Analgesic Effects of Bilateral Suprazygomatic Maxillary Nerve Block Using Bupivacaine and Dexmedetomidine in Children Undergoing Cleft Palate Repair Under General Anesthesia:Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
January 14, 2018 (Actual)
Primary Completion Date
August 31, 2018 (Actual)
Study Completion Date
August 31, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Cleft palate (CP) is a common congenital malformation, with an incidence ranging from 0.1 to 1.1 per 1000 births depending on the population group (liau et al, 2010). Early surgery is necessary to reduce phonation and feeding difficulties and reduce complications such as frequent sinusitis and other respiratory tract infections (Takemura et al., 2002). CP repair is painful, necessitating high doses of intravenous (I.V.) opioids. Therefore, the risk of postoperative respiratory depression and airway obstruction is important, and continuous monitoring is required during the initial 48h postoperatively (Roulleau et al, 2003). Maxillary nerve block using the suprazygomatic approach is used in children since it presents a lower rate of complications (Captier et al, 2009). By this way, one can reach the nerve as it exits the skull at the foramen rotundum within the pterygopalatine fossa, before the location where its nervous branches innervate the palate (Prigge et al, 2014). This simple, reliable and almost risk-free approach can yield an effective and prolonged anesthesia with a clear decreased use of morphine agents during and after cleft lip-palate surgery in small children (Mesnil et al, 2010). The nerve block must be bilateral. The local anesthetic (LA) is directly injected in the middle part of the fossa at a distance from the foramen rotundum to avoid any trauma to the nerve or vascular injury, as soon as the tip of the needle has crossed the temporal muscle (Binet et al, 2015). Various adjuvants to local anesthetics to increase the duration of block are described in the literature and used in the daily clinical practice. Dexmedetomidine is a selective alpha 2 (α2) adrenergic agonist with both analgesic and sedative properties. Animal studies showed that perineural dexmedetomidine added to bupivacaine or ropivacaine prolongs the duration of sensory and motor block (Brummett et al, 2011). Other clinical studies investigated the use of dexmedetomidine in patients undergoing ulnar nerve, axillary brachial and greater palatine nerve blocks, showed faster onset time and longer duration of block (Marhofer et al, 2013/ Esmaoglu et al, 2010& Obayah et al, 2010).
Detailed Description
Preoperative assessment: The day prior to surgery, all patients will undergo pre-anesthetic checkup including detailed history, physical, systemic examination and weight of the patient. All patients will be investigated for exclusion of any of the above mentioned contraindications. Laboratory work needed will include: Complete Blood Count (CBC); Prothrombin Time and Concentration (PT& PC); Partial Thromboplastin Time (PTT) and Bleeding Time (BT). All children will be kept nil per mouth 6-8 h for solids and 2 h for clear liquids. Preparation of the patient: Written consent and emergency resuscitation equipments including airway devices, pediatric advanced life support drugs for LA toxicity will be available. Intraoperative management: All patients in this study will be anesthetized by the same team of anesthesiologists and operated upon by the same surgeon who will be unaware of the study medications. General anesthesia will be standardized for all patients in both groups using 8 MAC sevoflurane in 100% O2 with appropriate size face mask. Intraoperative monitoring will include ECG, pulse oximetry, noninvasive blood pressure, capnography and temperature probe. After intravenous access securing, endotracheal intubation with appropriate size to the patient's age will be performed after administration of 2 mg/kg propofol. After orotracheal intubation, assisted mechanical ventilation using Ayre's T- piece will be used to maintain end-tidal carbon dioxide at 35±5 mmHg. General anesthesia will be maintained with 2-3 MAC sevoflurane. Intraoperatively, patients will receive an infusion of normal saline 0.9% solution 4ml/ kg / h. Bilateral SMB will be performed before surgery in anesthetized children, after aseptic preparation of the skin. The patient will be in supine position with the head in neutral position. The puncture site will be at the frontozygomatic angle, at the junction of the upper edge of the zygomatic arch and the frontal bone. A needle with 50 mm length and 25 gauge will be inserted perpendicular to the skin. It will be advanced to reach the greater wing of sphenoid at approximately 20 mm depth, then withdrawn a few millimeters and will be redirected toward the nasolabial fold in a 20° forward and 10° downward direction. The progression in the pterygopalatine fossa will be 35 to 45 mm. Loss of resistance after passing through the temporalis muscle will assist in determining the puncture depth. After a negative blood aspiration test, 0.2 ml/kg of the blinded study solution will be injected on each side (Captier et al, 2009). MAP, HR, SPO2 and end-tidal CO2 will be recorded before induction of anesthesia, before block, after the block and every 10 minutes till end of surgery. Skin incision will be made 20 minutes after SMB block. An increase in HR and MAP above 20% of baseline values with skin incision will be considered as a sign of inadequate analgesia. In this case, fentanyl 1 µg/kg will be given intravenously, and the case will be excluded from the study. Immediate complications related to regional anesthesia will be recorded: Systemic toxicity related to local anesthetics (seizures, heart rhythm, or conduction disorder) Bleeding at puncture site Pupil alteration and ocular lesion Before the end of surgery, IV paracetamol 15 mg/kg and dexamethasone 0.2 mg/kg will be administered. After completion of the surgical procedure, extubation will be done after ensuring adequate orogastric suction and patients will be transferred to the postanesthesia care unit (PACU). In PACU: MAP, HR, modified CHEOPS, POV and sedation score will be recorded on admission to PACU, 1, 4, 8, 12, 18, 24h postoperatively by an observer who will be unaware of the study protocol. Postoperative pain will be measured using a modified Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) (Taddio et al, 1995). CHEOPS = SUM (points for all 6 parameters) Interpretation: minimum score: 4 maximum score: 13 Patients with modified CHEOPS > 6 will be given rescue analgesia with 15 mg/kg paracetamol intravenously. Those with modified CHEOPS of 4-5 will be given paracetamol 25-40 mg/kg as suppository. Pain scores will be recorded every 10 minutes after administration of rescue analgesia to evaluate pain relief or need for further rescue analgesia. The number of children who will need postoperative rescue analgesics and the duration of analgesia that will be taken at the time when an analgesic is required will be recorded. Postoperative vomiting episodes will be recorded and treated with intravenous metoclopramide 0.5 mg/kg. Postoperative sedation will be assessed using sedation score described by Culebras et al, 2001 (1. Awake and alert. 2. Sleeping but easily arouses to voice or light touch. 3. Arouses to loud voice or shaking. 4. Arouses with painful stimuli only. 5. Unarousable). Delayed complications of the blocks will be also investigated and recorded as hematoma, restricted mouth opening, vision, sensory or motor deficit, eating disorder, and local infection. The parents will be asked to evaluate their satisfaction regarding pain control at the end of 48h postoperatively through 5-point Likertscale (1 = very satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied, 5 = very dissatisfied). Patients will be discharged from the hospital when they are pain free and there is no other medical reason to admit them to a surgical ward.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cleft Palate
Keywords
suprazygomatic block, dexmedetomidine

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
comparison of the analgesic effect of adding dexmedetomidine to bupivacaine with the analgesic effect of using bupivacaine alone in bilateral SMB for children undergoing CP repair under general anesthesia.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The trial will be planned that neither the doctors (investigators) nor the patients' guardians or even children themselves will be aware of the group allocation and drug received. The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection.
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bupivacaine
Arm Type
Active Comparator
Arm Description
Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%).
Arm Title
Dexmedetomidine
Arm Type
Active Comparator
Arm Description
Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Intervention Description
The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection. Patients will be randomly allocated into two groups of 40 patients each: Group A: will receive 0.2 ml/kg/side of bupivacaine (0.125%).
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Intervention Description
Group B: will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
Intervention Type
Drug
Intervention Name(s)
paracetamol
Intervention Description
paracetamol
Primary Outcome Measure Information:
Title
modified Children's Hospital of Eastern Ontario Pain Scale (CHEOPS)
Description
postoperative pain assessment in children minimum score: 4, maximum score: 13 Patients with modified CHEOPS > 6 will be given rescue analgesia
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
time to first analgesia
Description
time of intravenous paracetamol requirment postoperatively
Time Frame
24 hours
Title
5-point Likert scale
Description
parent satisfaction score (1 = very satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied, 5 = very dissatisfied)
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age between 1 and 5 years Children scheduled for primary surgery for soft palate cleft or soft and hard palate clefts Gender: both Exclusion Criteria: Parent refusal History of developmental delay or mental retardation, which will make observational pain intensity assessment difficult Hypersensitivity to any local anesthetics Bleeding diathesis Children with co-morbid conditions like congenital heart disease, respiratory pathology and central nervous system disorders Skin lesions or wounds at the puncture site of the proposed block
Facility Information:
Facility Name
Assiut University Hospital
City
Assiut
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Suprazygomatic Block in Cleft Palate Surgery in Children

We'll reach out to this number within 24 hrs